Thalys(SH:603716) Ge Long Hui A P P·2026-01-29 09:25Core Viewpoint - The company, Saily Medical, is expected to report a significant net loss for the year 2025, with projections indicating a loss between 160 million to 209 million RMB for net profit attributable to shareholders, and a loss between 180 million to 230 million RMB for net profit after deducting non-recurring gains and losses. This downturn is primarily attributed to a decline in operating revenue and increased R&D expenditures in the smart medical field [1][2]. Group 1: Financial Projections - The estimated net profit attributable to shareholders for 2025 is projected to be between -160 million to -209 million RMB [1] - The estimated net profit after deducting non-recurring gains and losses for 2025 is projected to be between -180 million to -230 million RMB [1] Group 2: Reasons for Performance Decline - The decline in operating revenue is due to the company's strategic decision to focus on core business development, resulting in the transfer of certain subsidiaries, which will no longer be included in the consolidated financial statements [1] - The company is undergoing a strategic transformation, and the lack of renewal arrangements for certain business contracts, combined with industry policy impacts, has led to a decrease in operating revenue [1] - Increased R&D investments in the smart medical field have negatively impacted profits due to higher R&D expenses [2]